Chemoinformaics analysis of salicylic acid 2-beta-D-glucoside
| Molecular Weight | 299.255 | nRot | 4 |
| Heavy Atom Molecular Weight | 284.135 | nRig | 13 |
| Exact Molecular Weight | 299.077 | nRing | 2 |
| Solubility: LogS | -1.03 | nHRing | 1 |
| Solubility: LogP | -0.319 | No. of Aliphatic Rings | 1 |
| Acid Count | 1 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 36 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 21 | No. of Aromatic Carbocycles | 1 |
| nHetero | 8 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 15 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 13 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 8 | No. of Arom Bond | 6 |
| nHA | 8 | APOL | 38.1279 |
| nHD | 4 | BPOL | 20.2561 |
| QED | 0.456 |
| Synth | 3.322 |
| Natural Product Likeliness | 1.498 |
| NR-PPAR-gamma | 0.004 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.014 |
| HIA | 0.666 |
| CACO-2 | -6.347 |
| MDCK | 0.0000362 |
| BBB | 0.253 |
| PPB | 0.296235 |
| VDSS | 0.266 |
| FU | 0.492328 |
| CYP1A2-inh | 0.078 |
| CYP1A2-sub | 0.03 |
| CYP2c19-inh | 0.022 |
| CYP2c19-sub | 0.055 |
| CYP2c9-inh | 0.004 |
| CYP2c9-sub | 0.082 |
| CYP2d6-inh | 0.018 |
| CYP2d6-sub | 0.121 |
| CYP3a4-inh | 0.013 |
| CYP3a4-sub | 0.014 |
| CL | 1.655 |
| T12 | 0.913 |
| hERG | 0.2 |
| Ames | 0.049 |
| ROA | 0.026 |
| SkinSen | 0.116 |
| Carcinogencity | 0.031 |
| EI | 0.227 |
| Respiratory | 0.032 |
| NR-Aromatase | 0.005 |
| Antiviral | Yes |
| Prediction | 0.777137 |